Clark Estates Inc. NY Sells 75,123 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Clark Estates Inc. NY reduced its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 39.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 115,000 shares of the company’s stock after selling 75,123 shares during the period. GE HealthCare Technologies makes up approximately 2.0% of Clark Estates Inc. NY’s holdings, making the stock its 11th largest holding. Clark Estates Inc. NY’s holdings in GE HealthCare Technologies were worth $10,793,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Glenmede Trust Co. NA grew its holdings in shares of GE HealthCare Technologies by 0.6% in the 3rd quarter. Glenmede Trust Co. NA now owns 30,173 shares of the company’s stock worth $2,832,000 after purchasing an additional 180 shares during the last quarter. Cynosure Group LLC grew its stake in GE HealthCare Technologies by 57.6% during the third quarter. Cynosure Group LLC now owns 32,532 shares of the company’s stock worth $3,053,000 after buying an additional 11,890 shares during the last quarter. Townsquare Capital LLC raised its position in GE HealthCare Technologies by 21.5% in the 3rd quarter. Townsquare Capital LLC now owns 7,722 shares of the company’s stock valued at $725,000 after purchasing an additional 1,366 shares during the last quarter. Baldwin Investment Management LLC boosted its stake in GE HealthCare Technologies by 12.9% in the third quarter. Baldwin Investment Management LLC now owns 6,673 shares of the company’s stock worth $626,000 after purchasing an additional 760 shares in the last quarter. Finally, Avestar Capital LLC bought a new stake in shares of GE HealthCare Technologies during the third quarter worth $237,000. 82.06% of the stock is owned by institutional investors and hedge funds.

GE HealthCare Technologies Stock Down 0.2 %

GE HealthCare Technologies stock opened at $82.51 on Wednesday. The company has a 50 day moving average of $88.27 and a 200-day moving average of $83.62. The company has a quick ratio of 0.98, a current ratio of 1.23 and a debt-to-equity ratio of 1.12. GE HealthCare Technologies Inc. has a twelve month low of $66.39 and a twelve month high of $94.55. The stock has a market capitalization of $37.70 billion, a PE ratio of 22.67, a price-to-earnings-growth ratio of 2.96 and a beta of 1.24.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its earnings results on Wednesday, October 30th. The company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.06 by $0.08. The firm had revenue of $4.86 billion during the quarter, compared to analyst estimates of $4.87 billion. GE HealthCare Technologies had a net margin of 8.56% and a return on equity of 25.19%. The company’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.99 EPS. On average, equities research analysts anticipate that GE HealthCare Technologies Inc. will post 4.3 EPS for the current fiscal year.

GE HealthCare Technologies Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Tuesday, January 14th will be issued a dividend of $0.035 per share. The ex-dividend date of this dividend is Tuesday, January 14th. This is an increase from GE HealthCare Technologies’s previous quarterly dividend of $0.03. This represents a $0.14 dividend on an annualized basis and a dividend yield of 0.17%. GE HealthCare Technologies’s dividend payout ratio (DPR) is presently 3.30%.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. UBS Group downgraded shares of GE HealthCare Technologies from a “neutral” rating to a “sell” rating and reduced their price target for the stock from $84.00 to $74.00 in a research report on Thursday, September 26th. BTIG Research upgraded shares of GE HealthCare Technologies from a “neutral” rating to a “buy” rating and set a $100.00 target price on the stock in a research report on Wednesday, September 18th. JPMorgan Chase & Co. initiated coverage on shares of GE HealthCare Technologies in a report on Monday, September 9th. They issued a “neutral” rating and a $90.00 price target for the company. Redburn Atlantic upgraded GE HealthCare Technologies to a “strong-buy” rating in a research report on Thursday, August 1st. Finally, Evercore ISI upped their price objective on GE HealthCare Technologies from $98.00 to $102.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, five have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, GE HealthCare Technologies has a consensus rating of “Moderate Buy” and a consensus price target of $94.36.

Insider Buying and Selling at GE HealthCare Technologies

In other GE HealthCare Technologies news, CEO Roland Rott sold 3,577 shares of the business’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $86.48, for a total transaction of $309,338.96. Following the sale, the chief executive officer now directly owns 24,298 shares of the company’s stock, valued at $2,101,291.04. The trade was a 12.83 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.27% of the company’s stock.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.